Delving into the Latest Updates on Elcatonin with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Elcatonin (JP17/INN)

+ [7]

Target

CALCR

Action

inhibitors

Mechanism

CALCR inhibitors(Calcitonin receptor inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication

Familial Paget's Disease of BoneHypercalcemiaOsteoporosis

Inactive Indication

HemiplegiaStroke

Originator Organization

Asahi Kasei Corp.

Active Organization

Asahi Kasei Corp.

Shandong Luye Pharmaceutical Co., Ltd.

Inactive Organization

Asahi Kasei Pharma Corp.

Drug Highest PhaseApproved

First Approval Date

Japan (15 Jun 1982),

Osteoporosis

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC148H244N42O47

InChIKeyDDPFHDCZUJFNAT-PZPWKVFESA-N

CAS Registry60731-46-6

Sequence Code 1000323

Source: *****

INTRODUCTION AND IMPORTANCEAlthough corticosteroids are effective for bronchial asthma, they are associated with various side effects, such as osteonecrosis of the femoral head and tibial condyle and osteoporosis. Here, we report a patient who was on corticosteroids for a long period of time due to severe asthma, which was thought to have led to lunate osteonecrosis of both wrist joints. Calcitonin (elcatonin), an osteoporosis drug, was administered to the wrist joint.CASE PRESENTATIONAllergy to anesthetics and various non-steroidal anti-inflammatory drugs (NSAIDs) made surgical treatment not possible and pain control difficult. In addition, pain in the wrist joint interfered with activities of daily living (ADLs). When calcitonin was administered intra-articularly into the wrist joint, the pain in the wrist joint was relieved and ADLs were improved. However, the pain-suppressing effect lasted only 1 week, and pain returned to the original state by the second week after treatment. Repeated injections were necessary every 2 weeks.CLINICAL DISCUSSIONThis is the first report of the effectiveness of intra-articular calcitonin in a patient with osteonecrosis of the lunate. This treatment may be applicable to patients with allergies to anesthesia and NSAIDs.CONCLUSIONIn the present case, calcitonin administered intra-articularly to the wrist appeared to be effective in pain control for steroid-induced lunate osteonecrosis.

01 Jan 2023·BioMed Research International

Retracted: Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Author: International, BioMed Research

[This retracts the article DOI: 10.1155/2022/1213278.].

01 Jul 2022·International Journal of Hematology

Diffuse 18F-fluorodeoxyglucose uptake in the bone marrow of an elderly man with B-cell lymphoma

Letter

Author: Sakata, Etsuro ; Notohara, Kenji ; Nakatani, Koya ; Ueda, Yasunori ; Saito, Kenki

An 89-yr-old man with a history of right lung adenocarcinoma, left lung squamous cell carcinoma, and penile squamous cell carcinoma presented with lower back pain persisting for 1 mo and general pain and weakness in both lower limbs persisting for 10 days.A bone marrow biopsy revealed a monotonous increase in small lymphocytes with pale cytoplasm and CD20 positivity.To mitigate acute kidney injury with hypercalcemia, treatment with hydration, elcatonin, and zoledronic acid was initiated.Subsequently, rituximab and a reduced dose of THP-COP therapy (cyclophosphamide, pirarubicin, vincristine, and prednisolone) were started.The patient's renal function improved rapidly with the above treatment.Reduction in bone pain also improved his ability to perform activities of daily living.The soluble IL-2 receptor level after the second course of rituximab and THP-COP therapy was 380 U/mL, indicating dramatic improvement in the patient's condition.

100 Deals associated with Elcatonin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03287	Elcatonin	H05BA04	DB13742

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Familial Paget's Disease of Bone	Japan	Asahi Kasei Corp.	07 Feb 2006
Hypercalcemia	China	Shandong Luye Pharmaceutical Co., Ltd.	01 Jan 2000
Osteoporosis	Japan	Asahi Kasei Corp.	15 Jun 1982

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemiplegia	Phase 1	Japan	Asahi Kasei Pharma Corp.	01 Jul 2012
Stroke	Phase 1	Japan	Asahi Kasei Pharma Corp.	01 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2018	Not Applicable	Osteoporosis	-	Elcatonin	finhumwngv(avdzxghbqk) = nnosshtwif ahxrthxjgt (evwmearcbj )	Negative	23 Oct 2018
				Elcatonin (Control Group)	finhumwngv(avdzxghbqk) = svvofapinj ahxrthxjgt (evwmearcbj )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data